CD274 and non-small cell lung carcinoma: Also, the ORR of the placebo plus pembrolizumab group in this study (39.0%) was similar to that in the pembrolizumab monotherapy group of the phase III KEYNOTE-024 study (44.8%), which also included patients with previously untreated, PD-L1 TPS ≥ 50% NSCLC [5].